Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Acute Pain Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Acute Pain Overview | 14 | 1 |
| Pipeline Products for Acute Pain Comparative Analysis | 15 | 1 |
| Acute Pain Therapeutics under Development by Companies | 16 | 4 |
| Acute Pain Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Acute Pain Pipeline Products Glance | 21 | 4 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Unknown Stage Products | 24 | 1 |
| Acute Pain Products under Development by Companies | 25 | 4 |
| Acute Pain Products under Investigation by Universities/Institutes | 29 | 1 |
| Acute Pain Companies Involved in Therapeutics Development | 30 | 35 |
| AcelRx Pharmaceuticals, Inc. | 30 | 1 |
| Adynxx, Inc. | 31 | 1 |
| Amorsa Therapeutics Inc. | 32 | 1 |
| AnaBios Corporation | 33 | 1 |
| Anavex Life Sciences Corp. | 34 | 1 |
| AngioChem Inc. | 35 | 1 |
| Antibe Therapeutics, Inc. | 36 | 1 |
| AskAt Inc. | 37 | 1 |
| Cara Therapeutics, Inc. | 38 | 1 |
| Centrexion Therapeutics Corp | 39 | 1 |
| Charleston Laboratories, Inc. | 40 | 1 |
| ChironWells GmbH | 41 | 1 |
| Crescita Therapeutics Inc. | 42 | 1 |
| Cytogel Pharma, LLC | 43 | 1 |
| Dompe Farmaceutici S.p.A. | 44 | 1 |
| Grunenthal GmbH | 45 | 1 |
| Iroko Pharmaceuticals, LLC | 46 | 1 |
| KemPharm, Inc. | 47 | 1 |
| KPI Therapeutics, Inc. | 48 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 49 | 1 |
| Mallinckrodt Plc | 50 | 1 |
| Nanomerics Ltd | 51 | 1 |
| Nanotherapeutics, Inc. | 52 | 1 |
| Orbis Biosciences Inc | 53 | 1 |
| Orexo AB | 54 | 1 |
| Orion Oyj | 55 | 1 |
| Pacira Pharmaceuticals, Inc. | 56 | 1 |
| Phosphagenics Limited | 57 | 1 |
| Recro Pharma, Inc. | 58 | 1 |
| Scilex Pharmaceuticals, Inc. | 59 | 1 |
| Shulov Innovative Science Ltd. | 60 | 1 |
| Syntrix Biosystems, Inc. | 61 | 1 |
| Thar Pharmaceuticals, Inc. | 62 | 1 |
| Trevena, Inc. | 63 | 1 |
| Yungjin Pharm. Co., Ltd. | 64 | 1 |
| Acute Pain Therapeutics Assessment | 65 | 12 |
| Assessment by Monotherapy Products | 65 | 1 |
| Assessment by Combination Products | 66 | 1 |
| Assessment by Target | 67 | 3 |
| Assessment by Mechanism of Action | 70 | 3 |
| Assessment by Route of Administration | 73 | 2 |
| Assessment by Molecule Type | 75 | 2 |
| Drug Profiles | 77 | 96 |
| (acetaminophen + benzhydrocodone hydrochloride) IR Drug Profile | 77 | 6 |
| (acetaminophen + hydrocodone bitartarate) ER Drug Profile | 83 | 2 |
| (acetaminophen + tramadol hydrochloride) SR Drug Profile | 85 | 1 |
| (buprenorphine hydrochloride + naloxone hydrochloride) Drug Profile | 86 | 1 |
| (celecoxib + tramadol hydrochloride) Drug Profile | 87 | 2 |
| AAT-076 Drug Profile | 89 | 1 |
| alfentanil hydrochloride Drug Profile | 90 | 1 |
| AMS-410 FA Drug Profile | 91 | 1 |
| ANAVEX-1037 Drug Profile | 92 | 1 |
| ANAVEX-1066 Drug Profile | 93 | 1 |
| ANAVEX-1067 Drug Profile | 94 | 1 |
| ANAVEX-1079 Drug Profile | 95 | 1 |
| ANAVEX-1519 Drug Profile | 96 | 1 |
| ANG-2002 Drug Profile | 97 | 1 |
| ARX-04 Drug Profile | 98 | 5 |
| ATB-352 Drug Profile | 103 | 1 |
| AYX-1 Drug Profile | 104 | 2 |
| BBI-11008 Drug Profile | 106 | 1 |
| celecoxib Drug Profile | 107 | 1 |
| CL-108 Drug Profile | 108 | 2 |
| CR-4056 Drug Profile | 110 | 1 |
| Cyt-1010 Drug Profile | 111 | 2 |
| dexmedetomidine hydrochloride Drug Profile | 113 | 3 |
| DF-2593A Drug Profile | 116 | 1 |
| difelikefalin Drug Profile | 117 | 8 |
| Drug for Acute Pain Drug Profile | 125 | 1 |
| ECP-1014 Drug Profile | 126 | 1 |
| ET-1 Drug Profile | 127 | 1 |
| FY-101C Drug Profile | 128 | 1 |
| FY-103B Drug Profile | 129 | 1 |
| grapiprant Drug Profile | 130 | 2 |
| HPI-201 Drug Profile | 132 | 1 |
| HS-731 Drug Profile | 133 | 1 |
| ibuprofen Drug Profile | 134 | 1 |
| ibuprofen Drug Profile | 135 | 1 |
| ibuprofen Drug Profile | 136 | 1 |
| ketamine hydrochloride Drug Profile | 137 | 2 |
| lidocaine hydrochloride Drug Profile | 139 | 1 |
| meloxicam Drug Profile | 140 | 3 |
| meloxicam Drug Profile | 143 | 1 |
| meloxicam ER Drug Profile | 144 | 1 |
| Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain Drug Profile | 145 | 1 |
| MR-309 Drug Profile | 146 | 2 |
| NM-0127 Drug Profile | 148 | 1 |
| oliceridine Drug Profile | 149 | 5 |
| Omnitram Drug Profile | 154 | 1 |
| Peptides to Target TRPV1 for Pain and Itch Drug Profile | 155 | 1 |
| prednisone Drug Profile | 156 | 1 |
| Prostatic Acid Phosphatase Drug Profile | 157 | 1 |
| RO-656570 Drug Profile | 158 | 1 |
| Small Molecule to Block Nav1.9 Channel for Pain Drug Profile | 159 | 1 |
| Small Molecules to Block Nav 1.7 for Pain Drug Profile | 160 | 1 |
| Small Molecules to Block Nav 1.8 for Pain Drug Profile | 161 | 1 |
| Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain Drug Profile | 162 | 1 |
| T-109 Drug Profile | 163 | 1 |
| tapentadol hydrochloride Drug Profile | 164 | 2 |
| TRV-734 Drug Profile | 166 | 2 |
| U-2902 Drug Profile | 168 | 2 |
| VPX-595 Drug Profile | 170 | 1 |
| ZEP-3 Drug Profile | 171 | 2 |
| Acute Pain Dormant Projects | 173 | 7 |
| Acute Pain Discontinued Products | 180 | 2 |
| Acute Pain Product Development Milestones | 182 | 11 |
| Featured News &Press Releases | 182 | 1 |
| Jul 26, 2016: Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam | 182 | 1 |
| Jun 28, 2016: AcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain | 183 | 1 |
| Jun 13, 2016: Charleston Laboratories and Daiichi Sankyo Announce FDA Acceptance of New Drug Application for CL-108 | 183 | 1 |
| Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings | 184 | 1 |
| Jun 08, 2016: Trevena Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain | 185 | 1 |
| May 26, 2016: AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX-04 following Ambulatory Abdominal Surgeries at Euroanaesthesia | 185 | 1 |
| May 24, 2016: New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140 | 186 | 1 |
| May 12, 2016: Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting | 187 | 1 |
| May 06, 2016: AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX-04 by Type of Abdominal Surgery | 187 | 1 |
| May 02, 2016: Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine | 188 | 1 |
| Mar 14, 2016: AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study | 189 | 1 |
| Mar 07, 2016: AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain | 190 | 1 |
| Feb 25, 2016: AcelRx Pharmaceuticals Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis | 190 | 1 |
| Feb 22, 2016: Trevena Receives FDA Breakthrough Therapy Designation for Oliceridine | 191 | 1 |
| Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting | 191 | 2 |
| Appendix | 193 | 2 |
| Methodology | 193 | 1 |
| Coverage | 193 | 1 |
| Secondary Research | 193 | 1 |
| Primary Research | 193 | 1 |
| Expert Panel Validation | 193 | 1 |
| Contact Us | 193 | 1 |
| Disclaimer | 194 | 1 |